Safety of Tirofiban in Endovascular Reperfusion Therapy for Acute Ischemic Stroke Due to Large Artery Occlusion

Zhou Tengfei,Zhu Liangfu,Li Tianxiao,Li Zhaoshuo,Li Qiang,Wu Liheng,Guan Min,Zhou Zhilong,He Yingkun,Liu Huanhuan

DOI: https://doi.org/10.3877/cma.j.issn.2095-5782.2020.01.005

2020-01-01

Abstract:Objective To investigate the relationship between intracranial bleeding complications after mechanical thrombectomy with or without tirofiban treatment. Methods Retrospective analysis on 173 patients with acute ischemic stroke due to large artery occlusion underwent endovascular treatment in our center were reviewed.. The baseline characteristics, ways and the efficacy of endovascular treatment, intracranial bleeding complications of two groups were retrospectively analyzed. Results 173 patients received endovascular treatment were categorized to tirofiban group (n=87) and no tirofiban group (n=86). Prevalence of diabetes (24.14% vs 10.47%, P=0.026) and posterior circulation in tirofiban group were higher than those in the no tirofiban group. The prevalence of atrial fibrillation was significantly higher in the no tirofiban group than that in the tirofiban group (P<0.001). The rate of final recanalization and good clinical outcome were comparable between the two groups. There were no differences in intracranial bleeding complications between the two groups. Conclusions Conjunctive use of tirofiban didn’t increase the risk of intracranial bleeding complications during the endovascular reperfusion therapy. Key words: Acute ischemic stroke; Tirofiban; Endovascular treatment